Contraceptive Use and Elective Terminations in Women Enrolled in the Glomerular Disease Collaborative Network

Abstract

approach to reducing or substituting immunosuppressive agents remains uncertain. In this survey, knowledge of the incidence of BK infection and the variability between sites will inform the design of a health care-embedded platform trial. More importantly, we have collected the information to conduct a process of research prioritization, in consultation with consumer groups, to define platform objectives that evaluate key intervention strategies and treatment arms that are currently preferred and commonly used by nephrologists. As most respondents to this survey supported the conduct of a randomized controlled trial to address this research question, a collaborative multicenter clinical study in Australia and New Zealand with a pragmatic trial design is a unique opportunity to address some of these evidence gaps and to inform future clinical management of recipients with BK viremia or BKVAN.